research Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
Search
for
Sort by
Research
450-480 / 1000+ results
research Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
research 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist
The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.
research Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
research Treatment of Alopecia Areata With Tofacitinib
Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
research A First Case of Complete Resolution of Hair Loss in a Patient With Rheumatoid Arthritis and Concomitant Alopecia Universalis Treated With Filgotinib
Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.
research Recovery of nail dystrophy potential new therapeutic indication of tofacitinib
Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
research A linear and reticulate crusted keratotic papulopustular eruption: a rare presentation of PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) complex
A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.
research Treatment of severe alopecia areata with baricitinib
Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
research 455 Molecular correlation with clinical outcomes in an open label clinical trial of oral tofacitinib in patients with alopecia areata
Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
research Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
research Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.
research Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study
Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.
research Hair loss disorders (alopecias)
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
research Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
research Treatment Challenges in Alopecia Areata: Insights From a Case of Baricitinib Therapy Failure
Baricitinib may not always prevent relapse in alopecia areata.
research Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (Preprint)
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
research 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
research Abstract 5357: Targeting mTORC1 suppresses proliferation of keratinocyte stem cells and inhibits skin tumor promotion in mice
Blocking mTORC1 reduces skin tumor growth in mice.
research Alopecia areata mit gutem Ansprechen auf Tofacitinib
Tofacitinib helped regrow hair in a woman with alopecia areata.
research Janus kinase inhibitors for alopecia areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research Excellent response to tofacitinib treatment in a patient with alopecia universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year
Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
research Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study
Baricitinib is effective for severe alopecia areata but has some side effects.
research Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study
Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
research Folliculitis decalvans responsive to tofacitinib: A case series
Tofacitinib may effectively treat folliculitis decalvans.